TY - JOUR
T1 - Important Role of Menarche in Development of Estrogen Receptor-Negative Breast Cancer in African American Women
AU - Ambrosone, Christine B.
AU - Zirpoli, Gary
AU - Hong, Chi Chen
AU - Yao, Song
AU - Troester, Melissa A.
AU - Bandera, Elisa V.
AU - Schedin, Pepper
AU - Bethea, Traci N.
AU - Borges, Virginia
AU - Park, Song Yi
AU - Chandra, Dhyan
AU - Rosenberg, Lynn
AU - Kolonel, Laurence N.
AU - Olshan, Andrew F.
AU - Palmer, Julie R.
N1 - Publisher Copyright:
© 2015 The Author.
PY - 2015/9/1
Y1 - 2015/9/1
N2 - Background: Menarche is a critical time point for diverging fates of mammary cells of origin. African American women have young age at menarche, which could be associated with their high rates of estrogen receptor-negative (ER-) breast cancer. Methods: In the AMBER Consortium, using harmonized data from 4426 African American women with breast cancer and 17 474 controls, we used polytomous logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for ages at menarche and first live birth (FLB), and the interval between, in relation to ER+ and ER-breast cancer. All statistical tests were two-sided. Results: Risk of ER-breast cancer was reduced with later age at menarche among both parous and nulliparous women (15 vs <11 years OR = 0.62, 95% CI = 0.48 to 0.81 and OR = 0.56, 95% CI = 0.29 to 1.10, respectively), with no effect of age at FLB. For ER+ breast cancer, the inverse association was weaker among nulliparous women. While longer intervals between menarche and FLB were associated with increased risk of ER+ breast cancer in a dose-response fashion (OR for 20 year interval = 1.39, 95% CI = 1.08 to 1.79, P trend =. 003), ER-risk was only increased for intervals up to 14 years and not beyond (P trend =. 33). Conclusions: While ER-breast cancer risk was markedly reduced in women with a late age at menarche, there was not a clear pattern of increased risk with longer interval between menarche and FLB, as was observed for ER+ breast cancer. These findings indicate that etiologic pathways involving adolescence and pregnancy may differ for ER-and ER+ breast cancer.
AB - Background: Menarche is a critical time point for diverging fates of mammary cells of origin. African American women have young age at menarche, which could be associated with their high rates of estrogen receptor-negative (ER-) breast cancer. Methods: In the AMBER Consortium, using harmonized data from 4426 African American women with breast cancer and 17 474 controls, we used polytomous logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for ages at menarche and first live birth (FLB), and the interval between, in relation to ER+ and ER-breast cancer. All statistical tests were two-sided. Results: Risk of ER-breast cancer was reduced with later age at menarche among both parous and nulliparous women (15 vs <11 years OR = 0.62, 95% CI = 0.48 to 0.81 and OR = 0.56, 95% CI = 0.29 to 1.10, respectively), with no effect of age at FLB. For ER+ breast cancer, the inverse association was weaker among nulliparous women. While longer intervals between menarche and FLB were associated with increased risk of ER+ breast cancer in a dose-response fashion (OR for 20 year interval = 1.39, 95% CI = 1.08 to 1.79, P trend =. 003), ER-risk was only increased for intervals up to 14 years and not beyond (P trend =. 33). Conclusions: While ER-breast cancer risk was markedly reduced in women with a late age at menarche, there was not a clear pattern of increased risk with longer interval between menarche and FLB, as was observed for ER+ breast cancer. These findings indicate that etiologic pathways involving adolescence and pregnancy may differ for ER-and ER+ breast cancer.
UR - http://www.scopus.com/inward/record.url?scp=84942253012&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942253012&partnerID=8YFLogxK
U2 - 10.1093/jnci/djv172
DO - 10.1093/jnci/djv172
M3 - Article
C2 - 26389154
AN - SCOPUS:84942253012
SN - 0027-8874
VL - 107
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
IS - 9
ER -